Prevalence of hepatitis A virus antibodies in Central-Eastern Poland – a comparative study (1990-2012)

• Authors: Dariusz Pachnia , Dorota Polz-Gruszka , Pawel Macielag , Malgorzata Polz-Dacewicz
• Languages of publication: EN

Abstracts

EN

Hepatitis A virus (HAV) is an hepatotropic human picornavirus that is associated only with acute infection of liver. This pathogen is mainly transmitted through the faecal-oral route, by person-to-person contact, and also contaminated drinking water and food. This reserach presenting the comparative seroepidemiological study (1990/1999/2012) on HAV infection was carried out in population from south-eastern Poland. Anti-HAV was tested in 613 subjects from 0 to over 60 years of age and the results were compared with those observed in 1990 and 1989/99. We also analyzed the number of vaccinations in the past decade and their role in preventing disease.

Keywords

EN

HAV; anti-HAV; seroprevalence

• Publisher: De Gruyter Open
• Journal: Current Issues in Pharmacy and Medical Sciences
• Year: 2014
• Volume: 27
• Issue: 1
• Pages: 17-19

Dates

published

1 - 6 - 2014

accepted

10 - 2 - 2014

received

28 - 1 - 2014

online

30 - 5 - 2014

Contributors

author

Dariusz Pachnia

• Department of Virology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Dorota Polz-Gruszka

• Department of Virology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Pawel Macielag

• Department of Virology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

author

Malgorzata Polz-Dacewicz

• Department of Virology, Medical University of Lublin, Chodzki 1, 20-093 Lublin, Poland

References

• 1. Bura M. et al.: Seroprevalence of hepatis A virus antibodies (anti- HAV) in adult inhabitants of Wielkopolska region, Poland - the role of Simple demographic factors. Ann. Agric. Environ. Med., 19, 738-741, 2012.
• 2. Centers for Disease Control and Prevention: prevention of hepatitis A though active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Recomm. Rep., 48, 1-37, 1999.
• 3. Chiroma M., et al.: Hepatitis A in Puglia (South Italy) after 10 years of universal vaccination: need for strict monitoring and catch-up vaccination. Infect. Dis., 12, 271, 1471-2334, 2012.[WoS]
• 4. Faillon S. et al.: Impact of travel on the seroprevalence of hepatitis A in children. J. Clin. Virol., 56, 46-51, 2013.[WoS]
• 5. Jacobsen K.H., Koopman J.S.: Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol. Infect., 132, 1005-1022, 2004.
• 6. Janaszek-Seydlitz W., Bucholc B., Wiatrzyk A.: Poziom przeciwciał przeciwko wirusowemu zapaleniu wątroby typu A u osób z terenu Warszawy. Przegl. Epidemiol., 61, 675-682, 2007.
• 7. Klevens R.M. et al.: Seroprevalence of Hepatitis A Virus Antibodies in the US: Results from the National Health and Nutrition Examination Surgey. Public Health Reports, 126, 522-32, 2011.
• 8. Knowles N.J. et al: Picornaviridae. [In:] King A.M.R., Adams MJ, Carstens EB, Lefkowitz EJ (editors) Virus taxonomy: classification and nomenclature of viruses: ninth report of the international committee on taxonomy of viruses. Elsevier, San Diego, pp 855-880, 2012
• 9. Krumbholz A. et al.: Prevalence of antibodies against hepatitis A virus among children and adolescents in Germany. Med. Microbiol.Immunol., doi 10.1007/s00430-013-0303-4[Crossref][WoS]
• 10. Kurkela S. et al.: Comparative hepatitis A seroepidemiology in 10 European countries. Epidemiol. Infect., 140, 2172-2181, 2012,doi:10.1017/S0950268812000015.[WoS]
• 11. Lee H.C. et al.: Changing epidemiological patterns of hepatitis A infection in Singapore. Ann. Acad. Med. Singapore, 40, 439-447, 2011.
• 12. MacDonald E.et al.: Increase in hepatitis A in tourists from Denmark, England, Germany, the Netherlands, Norway and Sweden returning from Egypt, November 2012 to March 2013. Euro Surveill., 18, pii=20468, 2013.
• 13. Polz-Dacewicz M., Policzkiewicz P., Badach Z.: Changing epidemiology of hepatitis A virus infection - a comparative study in Central Eastern Poland (1990-1999). Med Sci Monit 6, 989-993, 2000.
• 14. Van Herck K., Jacquet J.M., Van Damme P.: Antibody persistence and immune memory in healthy adults following vaccination with a two-dose inactivated hepatitis A vaccine: long-term follow-up at 15 years. J. Med. Virol., 83, 1885-91, 2011, doi: 10.1002/jmv.22200.[Crossref][WoS]
• 15. Whelan J. et al.: Evaluation of hepatitis a vaccine in post-exposure prophylaxis, the Netherlands, 2004-2012. PLoS One., 17;8; e:78914, 2013, doi: 10.1371/journal.pone.0078914.[Crossref]

Identifiers

DOI

10.2478/cipms-2014-0005